PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.

Abstract Immunotherapy targeting the programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) pathway has shown promising results in several malignancies. However, the prognostic significance of PD-L1 expression remains unknown in patients with upper tract urothelial carcinoma (UTUC). This study aimed to evaluate PD-L1 expression and its association with clinicopathological characteristics and oncological outcomes in UTUC patients. PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells (TIMCs), and E-cadherin and N-cadherin expression on tumor cells were assessed by immunohistochemistry in a cohort of 162 patients with UTUC. Associations of PD-L1 expression on tumor cells and TIMCs with clinicopathological characteristics and cancer-specific survival (CSS) were evaluated. Out of 162 patients, 20 (12.3%) and 35 (21.6%) had positive PD-L1 expression on tumor cells and TIMCs, respectively. Decreased E-cadherin expression was associated with PD-L1 positivity on tumor cells (P = 0.048) and PD-L1 negativity on TIMCs (P = 0.033). PD-L1 expression on tumor cells was higher in patients with preoperative chronic kidney disease (CKD) stage 4-5 than in those with no CKD or CKD stage 1-3 (P = 0.011). PD-L1 was differentially expressed in tumor cells and TIMCs in UTUC. Multivariate analyses revealed that PD-L1 expression on tumor cells independently predicted shorter CSS (P = 0.012), whereas PD-L1 expression on TIMCs independently predicted longer CSS (P = 0.034).
PMID
Related Publications

Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.

Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.

Authors

Mayor MeshTerms
Keywords

Cancer-specific survival

Immunotherapy

Programmed death-ligand 1

Upper tract urothelial carcinoma

Journal Title medical oncology (northwood, london, england)
Publication Year Start




PMID- 28409437
OWN - NLM
STAT- MEDLINE
DA  - 20170414
DCOM- 20170414
LR  - 20170414
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 34
IP  - 5
DP  - 2017 May
TI  - Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating
      mononuclear cells in upper tract urothelial carcinoma.
PG  - 94
LID - 10.1007/s12032-017-0941-2 [doi]
AB  - Immunotherapy targeting the programmed death-1 (PD-1) receptor/PD-1 ligand
      (PD-L1) pathway has shown promising results in several malignancies. However, the
      prognostic significance of PD-L1 expression remains unknown in patients with
      upper tract urothelial carcinoma (UTUC). This study aimed to evaluate PD-L1
      expression and its association with clinicopathological characteristics and
      oncological outcomes in UTUC patients. PD-L1 expression on tumor cells and
      tumor-infiltrating mononuclear cells (TIMCs), and E-cadherin and N-cadherin
      expression on tumor cells were assessed by immunohistochemistry in a cohort of
      162 patients with UTUC. Associations of PD-L1 expression on tumor cells and TIMCs
      with clinicopathological characteristics and cancer-specific survival (CSS) were 
      evaluated. Out of 162 patients, 20 (12.3%) and 35 (21.6%) had positive PD-L1
      expression on tumor cells and TIMCs, respectively. Decreased E-cadherin
      expression was associated with PD-L1 positivity on tumor cells (P = 0.048) and
      PD-L1 negativity on TIMCs (P = 0.033). PD-L1 expression on tumor cells was higher
      in patients with preoperative chronic kidney disease (CKD) stage 4-5 than in
      those with no CKD or CKD stage 1-3 (P = 0.011). PD-L1 was differentially
      expressed in tumor cells and TIMCs in UTUC. Multivariate analyses revealed that
      PD-L1 expression on tumor cells independently predicted shorter CSS (P = 0.012), 
      whereas PD-L1 expression on TIMCs independently predicted longer CSS (P = 0.034).
FAU - Zhang, Bo
AU  - Zhang B
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Yu, Wei
AU  - Yu W
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Feng, Xueru
AU  - Feng X
AD  - Department of Geriatrics, Peking University First Hospital, No. 8 Xi Shi Ku St., 
      West District, Beijing, People's Republic of China.
FAU - Zhao, Zheng
AU  - Zhao Z
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Fan, Yu
AU  - Fan Y
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Meng, Yisen
AU  - Meng Y
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Hu, Shuai
AU  - Hu S
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Cui, Yun
AU  - Cui Y
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - He, Qun
AU  - He Q
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Department of Pathology, Peking University First Hospital, No. 8 Xi Shi Ku St.,
      West District, Beijing, People's Republic of China.
FAU - Li, Dong
AU  - Li D
AD  - Department of Pathology, Peking University First Hospital, No. 8 Xi Shi Ku St.,
      West District, Beijing, People's Republic of China.
FAU - He, Zhisong
AU  - He Z
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Zhou, Liqun
AU  - Zhou L
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China.
FAU - Jin, Jie
AU  - Jin J
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China. [email protected]
FAU - Han, Wenke
AU  - Han W
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center, No. 8 Xi Shi Ku St., West
      District, Beijing, People's Republic of China. [email protected]
LA  - eng
PT  - Journal Article
DEP - 20170413
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Antigens, CD274)
RN  - 0 (CD274 protein, human)
SB  - IM
MH  - Aged
MH  - Antigens, CD274/*biosynthesis
MH  - Carcinoma, Transitional Cell/*metabolism/pathology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Lymphocytes, Tumor-Infiltrating/*metabolism/pathology
MH  - Male
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Ureteral Neoplasms/*metabolism/pathology
OTO - NOTNLM
OT  - Cancer-specific survival
OT  - Immunotherapy
OT  - Programmed death-ligand 1
OT  - Upper tract urothelial carcinoma
EDAT- 2017/04/15 06:00
MHDA- 2017/04/15 06:01
CRDT- 2017/04/15 06:00
PHST- 2016/09/24 [received]
PHST- 2017/04/01 [accepted]
AID - 10.1007/s12032-017-0941-2 [doi]
AID - 10.1007/s12032-017-0941-2 [pii]
PST - ppublish
SO  - Med Oncol. 2017 May;34(5):94. doi: 10.1007/s12032-017-0941-2. Epub 2017 Apr 13.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>